VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease.

VGLL4 promotes MAFLD progression by enhancing PDK4 transcription, with overexpression causing steatosis and knockout offering protection in mice.

• Why it matters: MAFLD lacks targeted therapies despite its global prevalence, highlighting the need to understand its regulatory mechanisms to develop effective treatments.
• What they did: Researchers used genetic models and molecular techniques to show that VGLL4 interacts with TEAD4 and CEBPA to activate Pdk4 expression, with PDK4 driving fatty liver pathology.
• The result: Disrupting VGLL4-TEAD interactions with a peptide reduces hepatic steatosis, suggesting that targeting this axis could be a promising therapeutic strategy for MAFLD.